Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
- 1 January 2004
- journal article
- review article
- Published by Elsevier in European Journal of Oncology Nursing
- Vol. 8, S16-S30
- https://doi.org/10.1016/j.ejon.2004.06.006
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trialJournal of Clinical Oncology, 2004
- Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerEuropean Journal Of Cancer, 2004
- Palliation of Oral Mucositis Symptoms in Pediatric Patients Treated With Cancer ChemotherapyCancer Nursing, 2003
- Current Canadian Experience With CapecitabineCancer Nursing, 2003
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002
- Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokineticsCancer Chemotherapy and Pharmacology, 2001
- Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patientsCancer, 2001
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Sorivudine and 5‐fluorouracil; a clinically significant drug‐drug interaction due to inhibition of dihydropyrimidine dehydrogenaseBritish Journal of Clinical Pharmacology, 1998
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976